Welcome to our dedicated page for Remsleep Holding news (Ticker: RMSL), a resource for investors and traders seeking the latest updates and insights on Remsleep Holding stock.
REMSleep Holdings, Inc. (RMSL) generates news primarily around its development and commercialization of CPAP mask interfaces for obstructive sleep apnea and related respiratory conditions. The company’s updates focus on the DELTAWAVE Nasal Pillows System, a patented and FDA‑cleared CPAP interface that REMSleep positions as a more comfortable alternative for pressure‑sensitive or non‑compliant CPAP users.
News coverage for REMSleep often highlights regulatory milestones, such as 510(k) clearance for the DELTAWAVE Nasal Pillows System and allowance of a utility patent for its nasal ventilation system by the United States Patent and Trademark Office. These announcements provide insight into the company’s progress in securing regulatory approvals and protecting its intellectual property.
Investors and industry observers can also follow commercial and distribution developments, including REMSleep’s formal agreement with 1800CPAP.com to feature the Deltawave CPAP mask system, Medicare registration approval for Deltawave, and the build‑out of independent sales representative networks. Press releases describe marketing strategies, national media plans, VA and DME outreach, and efforts to secure key distributor partnerships and clinical trial opportunities.
Another recurring theme in REMSleep news is operational and launch status updates. The company has issued shareholder letters and press releases discussing launch timelines, supply chain considerations such as medical‑grade silicone delivery and mold production, and the implementation of systems like enterprise resource planning to support inventory, quality, and sales management.
For those tracking RMSL, this news feed offers a centralized view of regulatory clearances, product launch progress, distributor interest, marketing initiatives, and SEC‑related disclosures. Bookmark this page to monitor how REMSleep advances Deltawave and its planned next‑generation CPAP interfaces in the sleep apnea device market.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
RemSleep Holdings (OTCQB: RMSL) has outlined key goals for 2023 in a recent update from CEO Tom Wood. The company aims for a successful FDA 510K submission for its DeltaWave CPAP mask by mid-March. Hiring Judy Strzepek has bolstered regulatory efforts, and the company is optimistic about the quicker path for future product approvals. RemSleep plans to enhance its sales strategy while addressing inventory challenges caused by market recalls. Additionally, promising internal results for new masks could lead to competitive advantages in treating COPD and CHF in sleep apnea patients.
Tampa, FL, Nov. 08, 2022 (GLOBE NEWSWIRE) -- RemSleep Holdings (OTCQB: RMSL) announced the commencement of final battery testing for its DeltaWave mask, expected to take 14-18 weeks. The delay is due to a GXP analysis issue regarding ISO testing protocols, necessitating new inventory and packaging. The company is also seeking patent rights for new masks and investigating clinical trial parameters for COPD and CHF treatment. CEO Tom Wood acknowledged setbacks and emphasized the importance of following proper protocols.
RemSleep Holdings (OTCQB: RMSL) announced that its common shares will start trading on the OTCQB Market as of July 27, 2022. This tier upgrade positions RemSleep among companies meeting high financial standards and regulatory compliance. CEO Tom Wood expressed optimism about expanding the shareholder base and enhancing transparency with investors. RemSleep manufactures medical devices for treating obstructive Sleep Apnea, leveraging over 30 years of CPAP experience. Investors can find real-time financial data and quotes on OTC Markets.